21290-1-AP

antibody from Proteintech Group

Targeting: SMYD2 HSKM-B, KMT3C, ZMYND14

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Antibody Data

Product number

21290-1-AP

Provider

Proteintech Group

Proper citation

Proteintech Cat#21290-1-AP, RRID:AB_10733881

Product name

SMYD2 antibody

Antibody type

Polyclonal

Description

KD/KO validated SMYD2 antibody (Cat. #21290-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, WB,ELISA.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.

Li J, Hong Z, Zhang J, Zheng S, Wan F, Liu Z, Dai B
Oncogene 2024 Mar;43(10):744-757

---

Modulation of Titin and Contraction-Regulating Proteins in a Rat Model of Heart Failure with Preserved Ejection Fraction: Limb vs. Diaphragmatic Muscle.

Vahle B, Heilmann L, Schauer A, Augstein A, Jarabo MP, Barthel P, Mangner N, Labeit S, Bowen TS, Linke A, Adams V
International journal of molecular sciences 2024 Jun 16;25(12)

---

The lysine methyltransferase SMYD2 facilitates neointimal hyperplasia by regulating the HDAC3-SRF axis.

Zhong X, Wei X, Xu Y, Zhu X, Huo B, Guo X, Feng G, Zhang Z, Feng X, Fang Z, Luo Y, Yi X, Jiang DS
Acta pharmaceutica Sinica. B 2024 Feb;14(2):712-728

---

Pharmacological inhibition of SMYD2 protects against cisplatin-induced renal fibrosis and inflammation.

Chen M, Zuo S, Chen S, Li X, Zhang T, Yang D, Zou X, Yang Y, Long H, Peng R, Yuan H, Guo B, Liu L
Journal of pharmacological sciences 2023 Sep;153(1):38-45

---

Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.

Li J, Wan F, Zhang J, Zheng S, Yang Y, Hong Z, Dai B
Molecular carcinogenesis 2023 Jul;62(7):940-950

---

STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells.

Pan K, Hu B, Wang L, Yuan J, Xu W
Journal of molecular neuroscience : MN 2022 Sep;72(9):2030-2044

---

Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation.

Su H, Meng C, Xu J, Su Z, Xiao C, Yang D
Cell death & disease 2022 Oct 21;13(10):890

---

Oleocanthal Attenuates Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence by Targeting SMYD2.

Siddique AB, Ebrahim HY, Tajmim A, King JA, Abdelwahed KS, Abd Elmageed ZY, El Sayed KA
Cancers 2022 Jul 21;14(14)

---

SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth.

Yu YQ, Thonn V, Patankar JV, Thoma OM, Waldner M, Zielinska M, Bao LL, Gonzalez-Acera M, Wallmüller S, Engel FB, Stürzl M, Neurath MF, Liebing E, Becker C
Cell death & disease 2022 Jan 12;13(1):52

---

Histone methyltransferase Smyd2 drives vascular aging by its enhancer-dependent activity.

Su Z, Su H, Xu J, Wei G, Qu L, Ni T, Yang D, Zhu Y
Aging 2022 Dec 28;15(1):70-91

---

SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer.

Wang Y, Jin G, Guo Y, Cao Y, Niu S, Fan X, Zhang J
Experimental cell research 2021 Jul 15;404(2):112649

---

SMYD2 suppresses APC2 expression to activate the Wnt/β-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.

Meng F, Liu X, Lin C, Xu L, Liu J, Zhang P, Zhang X, Song J, Yan Y, Ren Z, Zhang Y
American journal of cancer research 2020;10(3):997-1011

---

Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.

Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu J, Yao W, Yu G, An R, Chen Z, Ye Z, Xing J, Xiao K, Wu L, Xu H
Theranostics 2019;9(26):8377-8391

---

Proteomic analysis of seminal extracellular vesicle proteins involved in asthenozoospermia by iTRAQ.

Lin Y, Liang A, He Y, Li Z, Li Z, Wang G, Sun F
Molecular reproduction and development 2019 Sep;86(9):1094-1105

---

SMYD2 Drives Mesendodermal Differentiation of Human Embryonic Stem Cells Through Mediating the Transcriptional Activation of Key Mesendodermal Genes.

Bai HJ, Zhang P, Ma L, Liang H, Wei G, Yang HT
Stem cells (Dayton, Ohio) 2019 Nov;37(11):1401-1415

---

Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.

Zeng Y, Qiu R, Yang Y, Gao T, Zheng Y, Huang W, Gao J, Zhang K, Liu R, Wang S, Hou Y, Yu W, Leng S, Feng D, Liu W, Zhang X, Wang Y
Cell reports 2019 Nov 5;29(6):1482-1498.e4

---

Positive Expression of SMYD2 is Associated with Poor Prognosis in Patients with Primary Hepatocellular Carcinoma.

Zuo SR, Zuo XC, He Y, Fang WJ, Wang CJ, Zou H, Chen P, Huang LF, Huang LH, Xiang H, Liu SK
Journal of Cancer 2018;9(2):321-330

Western blot

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

mouse skeletal muscle tissue were subjected to SDS PAGE followed by western blot with 21290-1-AP(SMYD2 antibody) at dilution of 1:500

Sample type

tissue

Immunocytochemistry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunofluorescent analysis of Hela cells, using SMYD2 antibody 21290-1-AP at 1:25 dilution and Rhodamine-labeled goat anti-rabbit IgG (red). Blue pseudocolor = DAPI (fluorescent DNA dye).

Sample type

cell line

Immunohistochemistry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunohistochemical of paraffin-embedded human heart using 21290-1-AP(SMYD2 antibody) at dilution of 1:100 (under 10x lens)

Sample type

tissue